Category: Pharma, Life Sciences & Med Tech Players
-
Astellas settles parallel bladder treatment patent suits against India’s Lupin, Zydus: licensing deals worth combined $210 million
Japanese pharmaceutical giant Astellas has signed patent licensing agreements with Indian rivals Lupin and Zydus worth over $210 million, ending all ongoing litigation between the companies in the District of Delaware.
-
Appeals court persuades Grünenthal to drop unfair competition law injunctions (obtained in parallel to patent PIs) against Abdi Farma
Grünenthal had won two different types of injunctions against Amdi Farma over painkillers: a patent PI (on appeal) and unfair competition PIs, which have just been lifted.
-
Novo Nordisk files fresh semaglutide patent infringement suit in District of Delaware
Novo Nordisk has sued telehealth medication provider Hims & Hers over the infringement of one of its semaglutide patents, as the company faces headwinds over its weightloss drugs for the first time in nearly a decade.
-
UPC’s Hague LD grants Abbott two preliminary injunctions, assumes long-arm jurisdiction (Spain) over German defendants, clarifies urgency requirement
The Unified Patent Court’s Hague LD has provided clarifications on long-arm jurisdiction and urgency that have applicabiliy beyond these two cases.
-
Cross-border injunctions “have their place” but can be “big ask”: Sandoz Global Head of IP Julia Pike
There is a place for cross-border injunctions, but in more nuanced cases (such as Regeneron v. Advanz) it’s a “big ask” for one country to take that decision itself on behalf of all those other countries, the company’s Global Head of IP Julia Pike has told ip fray.
-
Roche’s Genentech, Organon, China’s Henlius settle major pertuzumab biosimilar litigation in U.S., UPC, NL, and Brazil (where it was most advanced)
A favorable validity decision by the Brazilian patent office and evidence preservation in the UPC contributed to this important biosimilar settlement.
-
“Principles of good litigation are universal”: Novo Nordisk Associate General Counsel Raquel Frisardi
“Whether you are litigating a contract, patent infringement, or a crime – there are certain behaviors as a litigator that get you better results, and I think those are very universal,” Raquel Frisardi told ip fray in an interview during Kisaco’s Patent Litigation Europe Summit.
-
“Limited” UPC impact on global pharma patent strategies, interim licenses debate, “seismic” changes at the PTAB: highlights from Patent Litigation Europe
An overwhelming consensus that life sciences companies prefer to litigate in parallel national courts rather than in the UPC, and an intense debate about the use of interim licenses over arbitration, were among the highlights of the second and third days of Kisaco’s annual Patent Litigation Europe in Amsterdam this week.
-
UPC success rate, EPO convergence debate and changing the “status quo”: day one of Patent Litigation Europe
ip fray breaks down the highlights from the first day of the fourth annual Patent Litigation Summit Europe, which featured a full day agenda dedicated to Unified Patent Court Litigation discussions.
-
Edwards faces heart valve patent infringement suit in District of Delaware
Edwards Lifesciences, an active enforcer of its heart valve technology patents in the Unified Patent Court, is now finding itself on the defending side of a patent infringement suit, filed by Israel-based rival Cardiovalve in the U.S.